NEW YORK — At OSN New York 2015, Christopher E. Starr, MD, FACS, talks about the challenges of treating ocular surface disorders and how clinicians can integrate new diagnostic tests in their practice to make more accurate diagnoses.
Author: Healio ophthalmology
NovaBay reports third-quarter net loss of $5.2 million
NovaBay Pharmaceuticals reported a net loss of $5.2 million, or $0.07 per share, in the third quarter compared with a net loss of $4.2 million, or $0.08 per share, in the same period of 2014, according to a press release. The increase was attributed to…
DME patients with vitreomacular adhesions may have better visual outcomes after anti-VEGF treatment
Anti-VEGF injections may improve visual outcomes in diabetic macular edema patients who have vitreomacular adhesions, according to the READ-3 study.The retrospective cohort study evaluated 26 DME patients who had a vitreomacular adhesion (VMA) and 98 D…
Clearside Biomedical closes $20 million series C financing
Clearside Biomedical has completed $20 million in series C financing, the company announced in a press release.Trout Capital served as an adviser to Clearside, and the financing round included new investors Aju IB Investment, Cormorant Asset Management…
VIDEO: Capsular tension rings and segments
NEW YORK — At OSN New York 2015, Elizabeth Yeu, MD, gives pearls on when to use different types of capsular tension rings and segments during cataract surgery.
Mundipharma acquires Merck’s glaucoma portfolio in areas outside US
Mundipharma Ophthalmology Products Limited has reached an agreement with Merck to acquire Merck’s glaucoma treatment portfolio in Australia, Canada, Latin America, the Middle East, Africa and New Zealand, the company announced in a press release.The portfolio includes Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution), Cosopt preservative-free, Saflutan (tafluprost), Timoptic (timolol maleate ophthalmic solution), Timoptic XE, Timoptic preservative-free, Trusopt (dorzolamide hydrochloride ophthalmic solution) and Trusopt preservative-free.
Imprimis reports 508% increase in revenue in third quarter
Imprimis Pharmaceuticals reported $2.7 million in total revenue in the third quarter, a 508% increase from $0.4 million reported in the same quarter of 2014, according to a press release. Sales for Tri-Moxi and Tri-Moxi-Vanc compounded injectable formulations were reported at $594,000 in the third quarter. Sales for combination topical eye drop formulations were reported at $263,000.
FDA grants Cellceutix rare pediatric disease designation for Kevetrin to treat retinoblastoma
Cellceutix has received rare pediatric disease designation from the FDA for Kevetrin to treat retinoblastoma, according to a press release.“Receiving the rare pediatric disease designation strengthens our portfolio and adds to our belief that Kevetrin has the potential to provide a meaningful therapeutic benefit to children and families affected by retinoblastoma, where enucleation of the eye is often the only solution,” Leo Ehrlich, CEO of Cellceutix, said in the release.
VIDEO: Surgeon discusses new extended range of astigmatism correcting IOLs
LAS VEGAS — At the American Academy of Ophthalmology annual meeting, Francis S. Mah, MD, talks about the new extended range of astigmatism correcting IOLs from Abbott Medical Optics. The lenses range up to 4.75 D within the corneal plane, which represents “a huge amount of astigmatism that can now be treated,” according to Mah.
Trabeculectomy has little impact on IOL power calculations
Trabeculectomy had a minimal effect on IOL power calculation despite significant changes in axial length and corneal power, according to a study.The prospective study included 34 eyes of 31 patients with a mean age of 53.35 years who were scheduled to …
Glaukos reports 57% increase in net sales in third quarter
Glaukos reported $19 million in net sales in the third quarter, a 57% increase from $12.1 million reported in the same quarter of 2014, according to a press release. The increase was attributed to the continued adoption of the iStent trabecular micro-b…
VIDEO: Patient response to anti-VEGF injections could be strong predictor of outcomes to therapy
LAS VEGAS — At the American Academy of Ophthalmology annual meeting, Pravin Dugel, MD, presents analysis of raw data from DRCR.net Protocol I, in which patient response to therapy after three injections of anti-VEGF was found to be predictive of long-term outcomes of continued treatment.
Early PPV may increase reattachment rates for macular detachment due to optic disc pit maculopathy
Early pars plana vitrectomy intervention of optic disc pits and serous macular detachments may increase the success of postoperative reattachment, according to a study.The retrospective multicenter study reviewed the charts of 32 eyes with optic disc p…
AGTC reports $11.1 million in revenue in third quarter
AGTC reported $11.1 million in total revenue in the third quarter compared with $705,000 in the same quarter of 2014, according to a press release. The increase was attributed to revenue from nonrefundable upfront fees that the company received from it…
Publication Exclusive: Noninvasive OCT angiography allows for detailed visualization of retinal vasculature
September’s announcement by Carl Zeiss Meditec that its AngioPlex OCT angiography technology had received 510(k) clearance from the FDA set the stage for other systems to likely also soon become commercialized in the U.S. The technology allows extreme close-up imaging of the retinal vasculature for assessing retinal vascular diseases and holds potential for guiding treatment decisions and monitoring patient responses to therapy.“Over the past 20 years, OCT has developed rapidly as a ‘noninvasive’ method of imaging for medical diagnosis and defining activity criteria, such as intra/subretinal fluid, hyper-reflective dots and (Read more...)
VIDEO: Surgeon reviews new iridectomy technique
LAS VEGAS — At the American Academy of Ophthalmology annual meeting, Priya Narang, MS, explains a new technique for performing peripheral iridectomy for eyes undergoing glued IOL surgery, specifically for eyes with large white-to white diameters.
Study finds 5% incidence of IOL opacification after DSEK
IOL opacification was identified in 5% of eyes that underwent Descemet’s stripping endothelial keratoplasty, according to one study.Investigators retrospectively analyzed the records of 160 pseudophakic eyes that underwent DSEK between 2003 and 2013. They assessed the interval between DSEK and diagnosis of IOL opacification, Snellen corrected distance visual acuity before and after opacification, IOL specifications and incidence of IOL exchange.
Phase 3 clinical trial enrollment begins for ocular allergy drug
Enrollment is underway for a second phase 3 clinical trial of Dextenza sustained release dexamethasone for treatment of allergic conjunctivitis, according to a press release from Ocular Therapeutix.The prospective, randomized, double-masked, vehicle co…
Omeros reports $3.3 million in revenue in third quarter
Omeros reported $3.3 million in revenue in the third quarter, which includes $3.2 million in Omidria sales, according to a press release. The company reported $214,000 in revenue in the third quarter of 2014.
VIDEO: Shire emerges in areas of unmet need in ophthalmology
LAS VEGAS — At the American Academy of Ophthalmology annual meeting, Shire CEO Flemming Ornskov, MD, MPH, discusses the company’s plans for progress and innovation in the ophthalmic industry.